Skip to content
HowShorted

Adamas Pharmaceuticals Inc short interest in 2021

In 2021, Adamas Pharmaceuticals Inc's disclosed short interest ran from 4.22% of shares outstanding on 15 Jan 2021 to 1.04% on 15 Nov 2021, a change of -3.18 percentage points. The year's high was 8.39% on 15 Apr 2021 and its low 1.04% on 15 Nov 2021, averaging 5.16% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.83 days on 15 Sep 2021. Full history: Adamas Pharmaceuticals Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021

Aggregate net short position time series for Adamas Pharmaceuticals Inc in 2021

2021 in figures

Start of year
4.22% (15 Jan 2021)
End of year
1.04% (15 Nov 2021)
Change
-3.18 pp
High
8.39% (15 Apr 2021)
Low
1.04% (15 Nov 2021)
Average
5.16%
Highest days to cover
18.83 (15 Sep 2021)
SEC filings marked
8

Every report in 2021

Adamas Pharmaceuticals Inc short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20214.22%8.26results (8-K)
29 Jan 20216.22%3.27
12 Feb 20213.24%1.00
26 Feb 20216.97%1.9810-K filed, results (8-K)
15 Mar 20217.88%4.37
31 Mar 20218.25%6.27
15 Apr 20218.39%11.79
30 Apr 20215.33%5.37
14 May 20215.04%7.9110-Q filed, results (8-K)
28 May 20214.87%10.41
15 Jun 20214.67%5.08
30 Jun 20214.72%8.09
15 Jul 20215.05%8.29
30 Jul 20215.42%13.88
13 Aug 20215.53%6.5810-Q filed, results (8-K)
31 Aug 20215.38%10.49
15 Sep 20215.51%18.83
30 Sep 20215.19%13.75
15 Oct 20213.51%1.00
29 Oct 20211.93%1.00
15 Nov 20211.04%1.0010-Q filed

See also: Adamas Pharmaceuticals Inc's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.